IgG4-related kidney disease in the elderly
Conditions
Interventions
Experimental group:Rituximab 1 g intravenous infusion is given at weeks 0 and 2. At 12 weeks, it is decided whether to add another 1 g depending on the status of B cell reconstitution.
Control group:Prednisone (or an equivalent dose of other glucocorticoids) at a starting dose of 0.8 g/kg/day orally is tapered according to the study protocol or adjusted according to the condition.
Sponsors
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
Male
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age > = 60 years 2. Newly diagnosed IgG4RKD: including IgG4 interstitial nephritis and IgG4 membranous nephropathy 3. Have not received any IgG4-RD related treatment
Exclusion criteria
Exclusion criteria: 1. Presence of other major complications; 2. Definite diagnosis or secondary to other kidney diseases 3. Have used immunosuppressive therapy, including hormones or various immunosuppressants, in the past 3 months; 4. Presence of other contraindications to the use of hormones, such as necrosis of the femoral head, active gastrointestinal bleeding 5. Combined with other conditions affecting the use of rituximab: (1) Active or occult infection, including: active bacterial, fungal, tuberculosis infection, HBV, CMV and other viral infections or incubation periods; (2) History of allergy to rituximab components 6. Clinician judgment that the patient is unable to comply with the study protocol 7. Participate in other clinical trials at the same time
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eGFR;Urine protein; | — |
Countries
China
Contacts
Public ContactKe Zheng
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed